Agentix Corp. Reports No Revenue and Decreased Net Loss for Fiscal Year Ending March 31, 2026

Agentix Corp., a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases, reported no revenue for the fiscal year ending March 31, 2026, consistent with the previous year. The company incurred a net loss of $485,636, a decrease from the $567,048 loss reported in the prior fiscal year. Total operating expenses decreased to $445,187 from $513,251, primarily due to reduced research and development costs, which fell to $125,079 from $180,987. The company’s accumulated deficit increased to $7,007,164 as of March 31, 2026, compared to $6,521,528 a year earlier.

Agentix has made strategic moves to enhance its operational capabilities, including the establishment of a subsidiary in Australia, Agentix Australia Pty Ltd, in September 2022. This subsidiary is intended to facilitate the development of the company’s key assets and participate in a tax rebate program for biotechnology and pharmaceutical development activities. The company is advancing two primary drug candidates, AGTX-2004 and AGTX-2003, both of which are designed to target peripheral cannabinoid receptors without crossing the blood-brain barrier. AGTX-2004 has received FDA clearance for an Investigational New Drug application and is preparing for Phase 1 clinical trials.

Operationally, Agentix reported a total of 40,066,951 shares of common stock outstanding as of March 31, 2026, with no full-time or part-time employees. The company’s cash position at the end of the fiscal year was $771, a significant decrease from $4,477 the previous year. The company’s liabilities increased to $3,596,282 from $3,204,523, largely due to rising accounts payable and related party debts. The company has indicated that it will need to secure additional funding to support its operations and development activities, as its current cash position is insufficient for ongoing expenses.

Looking ahead, Agentix Corp. faces substantial challenges, including the need for further financing to continue its operations and development plans. The company has entered into two Mezzanine Secured Notes with Gray’s Peak Private Credit LLC, totaling up to $700,000, but these are short-term obligations. Management has expressed uncertainty regarding its ability to raise sufficient funds, which raises doubts about the company’s ability to continue as a going concern. The company’s future performance will depend on its ability to execute its business plan, secure additional funding, and successfully advance its drug candidates through clinical trials.